Two Phase 3 Wins Give Bristol Myers New Options Beyond Its Current Portfolio

On October 12, Bristol Myers Squibb reported positive Phase 3 results for two experimental medicines. Admilparant met the primary endpoint in idiopathic pulmonary fibrosis at one of two tested doses. RYZ101, an actinium-based radiopharmaceutical obtained through the $4.1 billion acquisition of RayzeBio, improved progression-free survival in a rare group of neuroendocrine tumors.

The announcements arrived on the same day, but they address different parts of Bristol Myers’ pipeline. Admilparant could establish a new treatment mechanism in a relatively large chronic-disease market. RYZ101 could validate an acquired technology platform and establish Bristol Myers in actinium-based cancer therapy.

Both disclosures remain at the topline stage. Bristol Myers has not yet released the treatment-effect estimates, confidence intervals, p-values or detailed safety tables needed to assess either medicine’s clinical and commercial potential with precision.

Why Bristol Myers needs additional growth assets

Bristol Myers sells medicines across oncology, hematology, cardiovascular disease, immunology and neuroscience. Its current revenue base includes established products such as Eliquis and Opdivo, alongside newer medicines intended to carry growth as older products encounter generic competition.

In the second quarter of 2026, revenue increased 5.7% to $12.97 billion. Bristol Myers classifies $7.56 billion as Growth Portfolio revenue and $5.42 billion as Legacy Portfolio revenue, with a negative $9 million of other revenue bringing the components to the reported total.

Eliquis sits in the Legacy Portfolio, while Opdivo and its subcutaneous formulation, Opdivo Qvantig, sit in the Growth Portfolio. These classifications are additive at the portfolio level. The individual-product percentages illustrate concentration within total company revenue and should not be added to the portfolio percentages.

Growth Portfolio revenue rose 14.6% year over year, supported by newer medicines and product extensions. That progress is carrying an increasing share of the business, but several recently launched products are still small relative to Bristol Myers’ largest franchises. Cobenfy, acquired through the $14 billion purchase of Karuna Therapeutics, generated $63 million in the quarter. Pipeline conversion therefore remains central to the company’s longer-term revenue transition.

Admilparant produced a positive result at 60 mg

Idiopathic pulmonary fibrosis, or IPF, causes progressive and irreversible scarring of the lungs. As scarring worsens, the lungs lose capacity and patients find it increasingly difficult to breathe. Bristol Myers estimates that approximately 1.4 million people live with IPF globally and cites median survival of three to five years following diagnosis.

Admilparant is an oral inhibitor of lysophosphatidic acid receptor 1, known as LPA1. Activation of this receptor is involved in processes that promote fibrosis. Blocking the pathway is intended to slow the loss of lung function.

The ALOFT-IPF Phase 3 trial enrolled approximately 1,255 adults and randomly assigned them in equal proportions to admilparant at 60 mg twice daily, 120 mg twice daily or placebo. Participants could remain on stable background antifibrotic treatment, making the trial relevant to patients receiving existing therapies.

The primary endpoint measured the absolute change in forced vital capacity, or FVC, after 52 weeks. FVC records how much air a person can forcibly exhale after taking a full breath and is a standard measure of lung-function decline in IPF studies.

The 60 mg dose produced a statistically significant improvement versus placebo. The 120 mg dose also slowed FVC decline but failed to reach statistical significance. Bristol Myers reported low discontinuation rates due to adverse events, similar across both dose groups and placebo.

The dose result will require careful interpretation when detailed data arrive. A successful lower dose can support a registration package, particularly when it combines efficacy with acceptable tolerability. The absence of statistical significance at 120 mg creates uncertainty around the dose-response relationship. The eventual assessment will depend on the absolute FVC difference, variability between treatment groups, missing-data handling and consistency across prespecified patient subgroups.

Bristol Myers plans to discuss regulatory submissions with health authorities. A second Phase 3 study, ALOFT-PPF, is evaluating admilparant in approximately 1,057 patients with progressive pulmonary fibrosis arising from other interstitial lung diseases. Topline results are expected in early 2027.

RYZ101 validates the lead asset acquired with RayzeBio

The second result has a direct connection to Bristol Myers’ acquisition strategy. In February 2024, the company completed its purchase of RayzeBio, a biotechnology company focused on radiopharmaceuticals.

The original transaction valued RayzeBio’s equity at approximately $4.1 billion. Estimated cash acquired reduced the stated net purchase value to $3.6 billion. Bristol Myers primarily financed the acquisition with new debt.

RYZ101 is RayzeBio’s lead program. It combines DOTATATE, which binds to somatostatin receptors expressed by certain tumors, with actinium-225. Actinium-225 emits short-range, high-energy alpha particles that can damage the DNA of nearby cancer cells.

The ACTION-1 trial studied patients with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, whose disease had progressed following lutetium-177 therapy. The comparator group received the investigator’s choice of high-dose or high-frequency somatostatin analogues, everolimus or sunitinib.

At a planned interim analysis, RYZ101 produced a statistically significant improvement in progression-free survival as assessed through blinded independent review. Bristol Myers described the improvement as clinically meaningful and said the safety findings were consistent with RYZ101’s known profile.

This is the first positive Phase 3 result reported for an alpha-isotope targeted radiopharmaceutical. It therefore supports more than one drug candidate. It provides clinical validation for the actinium-based platform, tumor-targeting approach and manufacturing infrastructure that formed the rationale for buying RayzeBio.

The initial commercial population is narrower than the headline disease prevalence suggests. Bristol Myers estimates that about 18,000 patients are diagnosed with GEP-NETs each year in the United States and that 80% to 90% of tumors express somatostatin receptor 2. ACTION-1 enrolled patients who had already progressed following lutetium-177 treatment, reducing the directly addressable population to a later treatment setting.

What the disclosures establish

The two trials have cleared different technical risks.

For admilparant, the trial confirms that LPA1 inhibition can produce a statistically detectable effect in a large pivotal IPF study. The remaining work concerns the size, durability and clinical relevance of that effect, plus whether regulators accept the 60 mg dataset without requiring additional explanation of the 120 mg outcome.

For RYZ101, the readout shows that the acquired lead asset can outperform active treatment options in a randomized trial. Detailed data will determine the value of that advantage and the practical burden of delivering an actinium-based therapy. Manufacturing capacity, isotope availability, specialist treatment sites and radiation-handling requirements will all influence adoption.

Neither release disclosed an overall-survival result. Progression-free survival can support regulatory decisions in oncology, but duration of benefit and survival trends will affect physician uptake, reimbursement and commercial forecasts.

Financial capacity remains adequate, with less room for low-return acquisitions

Bristol Myers ended June with $11.46 billion of cash, cash equivalents and marketable debt securities. Total debt had a carrying value of $42.86 billion, comprising $768 million classified as current and $42.09 billion as long term. Subtracting the $11.46 billion liquidity balance produces net debt of approximately $31.40 billion.

During the first half of 2026, operations generated $4.50 billion of cash. The company paid $2.60 billion in dividends and repaid $1.70 billion of debt. Those two uses absorbed $4.30 billion, leaving approximately $0.20 billion before investing activities and other financing items. Cash and restricted cash declined by $1.50 billion over the six months.

The company also had an undrawn $5 billion revolving credit facility at June 30. That facility adds liquidity but is not cash and is excluded from the net-debt calculation.

Positive pivotal results improve the probability that prior research and acquisition spending will generate products. They do not yet establish returns on that capital. RayzeBio’s $4.1 billion equity purchase price covers RYZ101, earlier-stage programs, intellectual property and manufacturing capabilities. RYZ101’s eventual revenue therefore cannot be directly compared with the full acquisition price without accounting for development spending, manufacturing investment, launch costs, margins, taxes, timing and the residual value of the wider platform.

Evidence that will determine the investment value

Detailed presentations for both studies are the next important evidence. For admilparant, the absolute difference in FVC decline will show whether statistical success translates into a clinically persuasive benefit. Safety by dose, use alongside existing antifibrotics and subgroup consistency will influence its position in treatment.

For RYZ101, the progression-free-survival hazard ratio, median results and adverse-event profile will determine the strength of the regulatory and commercial case. Manufacturing readiness and access to actinium-225 will also affect the pace and scale of a launch.

The planned regulatory discussions for both programs, admilparant’s ALOFT-PPF result in early 2027 and eventual filing timelines will establish when either asset can begin contributing revenue. Until then, the October 12 announcements improve the probability of two future products without providing enough information for reliable peak-sales estimates.